FF-10832 Granted FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
The FDA grants orphan drug designation to support the development of therapies for rare diseases that affect fewer than 200,000 people in the U.S.1 Small patient populations can limit preclinical research and slow clinical trials, stalling progress in therapeutic development for rare diseases. The designation supports research and clinical development by providing 7-years marketing exclusivity and other financial incentives.
There are approximately 16,000 new cases of BTC in the U.S per year.2 Most (≥70%) patients present with unresectable or metastatic disease at diagnosis, and current treatments of surgery, chemotherapy, and radiation show limited efficacy in advanced stages. High recurrence (50–70%) and low 5-year survival rates (4–13%) highlight the urgent need for new and effective treatments.
Gemcitabine has been a key component of BTC treatment since its approval in the 1990s, with all major first line regimens currently containing gemcitabine.3 FF-10832's novel liposomal formulation of gemcitabine for intravenous administration is designed to enhance anti-tumor activity by prolonging plasma half-life and improving targeted delivery to tumors.
"BTCs are rare but aggressive malignancies associated with a poor prognosis and limited treatment options," said Susumu Shimoyama, president, FUJIFILM Pharmaceuticals U.S.A., Inc. "Receiving orphan drug designation highlights the significant unmet medical need that still remains and supports development of FF-10832 for patients with BTC who have few satisfactory options."
FF-10832 is manufactured by FUJIFILM Toyama Chemical, providing seamless CDMO end-to-end services for full integration from formulation development to GMP manufacturing. Fujifilm's investigational drug candidates FF-10502 and FF-10850 have also been granted orphan drug designations for cholangiocarcinoma and Merkel cell carcinoma, respectively.
About FUJIFILM
FUJIFILM Pharmaceuticals U.S.A., Inc., based in Boston, Massachusetts, specializes in next generation drug delivery system formulation and CDMO services for precision treatment and care. In addition, the Company builds and maintains relationships with medical institutions, academic partners, and industry partners to conduct clinical trials and advance development of unique therapeutic compounds in oncology pipelines. For more information, please visit www.fujifilmpharma.com.
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.
For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.
1 Food and Drug Administration (FDA). 2013. 21CFR Part 316 - Relevant Excerpts. Available at https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts, accessed 2025 May 10.
2 Lowe RC, Anderson CD. 2024. Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma. UpToDate [website]. Available at: https://www.uptodate.com/contents/epidemiology-risk-factors-anatomy-and-pathology-of-cholangiocarcinoma?search=cholangiocarcinoma&source=search_result&selectedTitle=4%7E145&usage_type=default&display_rank=4, accessed 2025 April 29.
3 Rizzo A, Brandi G. 2021. Cancer Treat Res Commun 27:100335, PMID: 33592561.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707338743/en/
Contacts
Media Michele DarnellFUJIFILM Holdings America CorporationE-mail: michele.darnell@fujifilm.com
Megan AugustineFUJIFILM Holdings America CorporationE-mail: megan.augustine.contractor@fujifilm.com
Other Contacts FUJIFILM Pharmaceuticals U.S.A., Inc.fphucontact@fujifilm.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA Announces Massive Recall of Popular Produce in 4 States and DC
The U.S. Food and Drug Administration announced a massive recall of 30 different kinds of produce over possible contamination. Recalled produce includes a wide variety, such as apples, sweet corn, asparagus, spinach, cilantro, lemons, cucumber and cauliflower, among others. The FDA in its recall announcement notes the produce might "be contaminated with fluid from a reach truck." The notice doesn't expand on what kind of fluid potentially contaminated the foods, or what kind of "reach truck" the fluids came from, though a reach truck often refers to a type of forklift used to transport large amounts of goods. UNFI General Corporate, a Rhode Island-based company, voluntarily issued the recall on July 10, 2025. The states impacted are New Jersey, New York, Maryland, Pennsylvania and the District of Columbia. The FDA also notes 213 cases of product are impacted by the recall, though it's not clear how many of each product are in each case. UNFI on its website notes the company works to provide products and services "for thousands of suppliers and retailers of all sizes." The company also on its website notes it provides "products to more than 30,000 locations throughout North America, including natural product superstores, independent retailers, conventional supermarket chains, ecommerce providers, and food service customers." Common types of fluids found on forklifts, or reach trucks, include brake fluid, engine oil and hydraulic fluid, according to the Fork Lift Tire Company. Hydraulic fluid is the main fluid used to raise and lower the forks used to move goods around. The news comes as food recalls are becoming more widespread, according to CNN. While data for 2025 isn't complete yet, because the year isn't over, the U.S. Public Interest Research Group reported an 8 percent rise in recalls in 2024 compared to 2023. The FDA reported 241 food and beverage recalls and alert notices in 2024, the group Announces Massive Recall of Popular Produce in 4 States and DC first appeared on Men's Journal on Jul 13, 2025


Business Insider
an hour ago
- Business Insider
Coelacanth Energy, Inc. (CEI) Gets a Buy from Roth MKM
In a report released yesterday, from Roth MKM initiated coverage with a Buy rating on Coelacanth Energy, Inc. and a price target of C$1.05. The company's shares closed last Friday at C$0.84. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The analyst consensus on Coelacanth Energy, Inc. is currently a Hold rating. Based on Coelacanth Energy, Inc.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$2.67 million and a GAAP net loss of C$3.62 million. In comparison, last year the company earned a revenue of C$2.85 million and had a GAAP net loss of C$1.2 million Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CEI in relation to earlier this year.
Yahoo
3 hours ago
- Yahoo
Bearish Bitcoin Trader Loses $92M as Surge Wipes Out $426M in Short Liquidations
More than $680 million in crypto positions were liquidated over the past 24 hours with short traders taking the bulk of the pain as a bitcoin (BTC) breakout above $121,000 triggered a chain reaction across derivatives markets. Roughly $426 million of the total liquidations came from bearish bets, according to Coinglass data, making it one of the largest weekend liquidation events in recent months. The largest single order, a $92.5 million BTC short, was flushed on HTX. BTC alone saw $291 million in forced closures, with futures tracking ether (ETH) and XRP (XRP) following at $68 million and $17 million, respectively. XLM (XLM) and pepecoin (PEPE) also posted elevated activity, signaling that the squeeze extended deep beyond major tokens. Meanwhile, dogecoin (DOGE), Solana's SOL (SOL), and SUI (SUI) saw rising open interest, though with relatively smaller drawdowns, indicative of higher spot-based demand. Liquidations occur when traders using leverage are forced to close their positions due to margin calls. While they often signal excessive positioning, they also serve as a reset mechanism for markets, flushing weak hands and clearing the way for new directional flow. Bitcoin's rally in the past week has sparked a broader breakout across major crypto assets. Traders say that market structure is evolving under the weight of institutional influence — with eyes on the $130,000 mark in the short in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data